David Olmos

Summary

Affiliation: Institute of Cancer Research
Country: UK

Publications

  1. doi request reprint Biological rationale and current clinical experience with anti-insulin-like growth factor 1 receptor monoclonal antibodies in treating sarcoma: twenty years from the bench to the bedside
    David Olmos
    Sarcoma Unit, The Royal Marsden NHS Foundation Trust, London, United Kingdom
    Cancer J 16:183-94. 2010
  2. doi request reprint Role of palliative chemotherapy in advanced epithelioid sarcoma
    Robin L Jones
    Sarcoma Unit, Royal Marsden Hospital, London, UK
    Am J Clin Oncol 35:351-7. 2012
  3. pmc Targeting the Insulin-Like Growth Factor 1 Receptor in Ewing's Sarcoma: Reality and Expectations
    David Olmos
    Sarcoma Unit, The Royal Marsden NHS Foundation Trust, London SW3 6JJ, UK
    Sarcoma 2011:402508. 2011

Detail Information

Publications3

  1. doi request reprint Biological rationale and current clinical experience with anti-insulin-like growth factor 1 receptor monoclonal antibodies in treating sarcoma: twenty years from the bench to the bedside
    David Olmos
    Sarcoma Unit, The Royal Marsden NHS Foundation Trust, London, United Kingdom
    Cancer J 16:183-94. 2010
    ..Despite these encouraging results, not all patients benefit from IGF-1R inhibition and consequently there is an urgent need for the identification of predictive markers of response...
  2. doi request reprint Role of palliative chemotherapy in advanced epithelioid sarcoma
    Robin L Jones
    Sarcoma Unit, Royal Marsden Hospital, London, UK
    Am J Clin Oncol 35:351-7. 2012
    ..The aim of this study was to investigate the response rate and progression-free survival in a series of epithelioid sarcoma patients treated with chemotherapy at a single referral center...
  3. pmc Targeting the Insulin-Like Growth Factor 1 Receptor in Ewing's Sarcoma: Reality and Expectations
    David Olmos
    Sarcoma Unit, The Royal Marsden NHS Foundation Trust, London SW3 6JJ, UK
    Sarcoma 2011:402508. 2011
    ..Despite, the initial promising results, not all patients benefit from IGF-1R inhibition, and consequently, there is an urgent need for the identification of predictive markers of response...